The EBMT activity survey 2008: impact of team size, team density and new trends
Authors:
- A GratwohlAGA Gratwohl
- H BaldomeroHBH Baldomero
- A SchwendenerASA Schwendener
- M GratwohlMGM Gratwohl
- J ApperleyJAJ Apperley
- K FrauendorferKFK Frauendorfer
- D NiederwieserDND Niederwieser
- 29 March 2010
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (2) , 174-191
Abstract
Six hundred and fifteen centers from 45 countries reported a total 30 293 HSCT to this 2008 EBMT survey with 26 810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphomas (56%; 89% autologous); solid tumors (6%; 96% autologous); and non-malignant disorders (6%; 88% allogeneic). There were more unrelated than HLA-identical sibling donors (49 vs 46%). The proportion of peripheral blood transplants remained stable with 99% for autologous and 70% for allogeneic HSCT. One fifth of the teams with >80 HSCT performed more than half of all HSCT. This trend towards teams with higher numbers of HSCT was stronger for allogeneic (Gini coefficient 57%) than for autologous HSCT (Gini coefficient 38%). Transplant rates (number of transplants per 10 million inhabitants) increased in a close to linear way with increasing team density (number of transplant teams per 10 million inhabitants) and without saturation (R2=0.54); this connection was even stronger for allogeneic HSCT (R2=0.67). These data illustrate status and trends for HSCT in Europe. They provide a rational basis for planning and patient counseling.Keywords
This publication has 24 references indexed in Scilit:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009Bone Marrow Transplantation, 2009
- The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapiesBone Marrow Transplantation, 2009
- Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)Best Practice & Research Clinical Haematology, 2008
- Predictability of hematopoietic stem cell transplantation ratesHaematologica, 2007
- Hematopoietic-Cell Transplantation at 50New England Journal of Medicine, 2007
- Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?Blood, 2007
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity surveyBone Marrow Transplantation, 2004
- Current trends in hematopoietic stem cell transplantation in EuropeBlood, 2002